Sean P. Duffy, serving as both Chief Executive Officer and a Director at Omada Health, Inc. (NASDAQ:OMDA), has completed a sequence of equity transactions spanning from June 24 to June 26, 2026. The executive's actions involved the exercise of stock options followed by the immediate sale of a portion of the acquired shares, resulting in total sales proceeds of $342,115.
These transactions were documented in an amended filing, which served to correct an inadvertent omission from an earlier report. During the specified period, Mr. Duffy acquired a total of 17,258 shares of Omada Health common stock through option exercises. The cost basis for these acquisitions totaled $111,054, with individual share prices ranging from $5.82 to $8.28. The acquisition and subsequent disposal of these shares were executed as part of same-day exercise-and-sale events.
Concurrently with the acquisitions, Mr. Duffy sold the entirety of the 17,258 shares obtained through option exercises. These sales generated proceeds ranging from $19.0033 to $20.9 per share. The sales were conducted pursuant to a 10b5-1 trading plan that was adopted by Mr. Duffy on March 13, 2026. This pre-arranged plan is designed to facilitate the buying and selling of company stock in compliance with insider trading regulations.
Following these recent transactions, Sean P. Duffy's direct ownership in Omada Health stands at 411,861 shares of common stock. Furthermore, he maintains an indirect holding of 851,659 shares through family trusts established for the benefit of his family members. While these shares are held in trust, Mr. Duffy has disclaimed beneficial ownership of them, except to the extent of his pecuniary interest in the trusts.
The timing of these transactions coincides with a notable upward trend in Omada Health's stock performance. Over the past six months, the shares have surged by 49%. The stock is currently trading at $22.98, supporting a market capitalization of $1.37 billion. According to analysis by InvestingPro, the stock appears to be trading at a premium relative to current valuation metrics, with assessments suggesting it may be overvalued at these levels. Despite this valuation perspective, analysts maintain a positive outlook on the digital health company's prospects.
InvestingPro provides additional exclusive insights for OMDA, offering deeper analysis into the company's financial health and market position. The platform includes strategies and valuation models to assist investors in evaluating the stock.
In broader corporate developments, Omada Health reported its financial results for the first quarter of 2026. The company posted an earnings per share (EPS) of -$0.05, which exceeded the forecasted loss of -$0.08. Revenue for the quarter reached $78 million, marking a 42% increase compared to the same period in the previous year. This positive earnings surprise has contributed to improved guidance and investor sentiment.
Analyst Constantine Davides from Citizens raised the price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. Davides noted that the company has been trading at 2.5 times the firm's 2026 revenue estimate.
In corporate governance updates, Omada Health held its 2026 Annual Meeting of Stockholders. During the meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors are set to serve until the 2029 annual meeting, providing continuity in leadership as the company navigates its growth phase.